BPC-157 appears to counteract oxidative stress damage through enhancement of antioxidant enzyme systems and reduction of reactive oxygen species in damaged tissues
The MariTide Phase 2 data presented in November 2024 were highly significant: MariTide demonstrated robust weight loss at 52 weeks with no plateau meaning continued weight loss trajectory at the end of the study period, unlike semaglutide and tirzepatide which show plateau effects and significant improvements in cardiometabolic parameters

For Western blotting and immunofluorescence staining, the following antibodies were used: LOXL2 rabbit monoclonal (Abcam, ab179810), LOX rabbit polyclonal (Invitrogen, PA1-46020), LOXL1 mouse monoclonal (Santa Cruz, sc-166632), LOXL3 rabbit polyclonal (Santa Cruz, sc-68939), VAP-1 (AOC3) mouse monoclonal antibody (Santa Cruz, sc-373924), Collagen I monoclonal antibody (Invitrogen, MA1-26771), Collagen IV polyclonal antibody (Assay Biotech, C0157), GAPDH mouse monoclonal (Novus Bio, NB300221), goat anti-mouse IgG (H + L)-HRP conjugate (Biorad 1706516), AffiniPure goat anti-rabbit IgG (H + L)-HRP conjugate (Jackson ImmunoResearch, 111035144), Cy5 AffiniPure Goat Anti-Rabbit IgG (H + L) (Jackson ImmunoResearch, 111175144), Alexa Fluor 568 Goat anti-Rabbit IgG (H + L) Secondary Antibody (Invitrogen, A-11011), Alexa Fluor 488 Donkey anti-Mouse IgG (H + L) Secondary Antibody (Invitrogen, A-21202) and fluorescein (DTAF) streptavidin (Jackson ImmunoResearch, 016010084)

No content herein should be construed as medical, clinical, or therapeutic guidance
It was shown that Polyunsaturated fatty acids (PUFA) of arachidonic acid (AA)/adrenaline (AdA) were acylated and esterified to AdA-Phosphatidyl Ethanolamine (AA-PE) and AA-PE with the participation of ACSL4, coenzyme A, and lysophosphatidylcholine acyltransferase-3 (LPCAT3)